Access to Medicine Index: How Nigeria, Uganda, Kenya Face Gaps in Affordability, Availability of Essential Drugs

Access to Medicine Index: How Nigeria, Uganda, Kenya Face Gaps in Affordability, Availability of Essential Drugs

Follow THISDAYLIVE on GoogleAdd us as a preferred source to see more of our stories in Google Follow us on Google Despite progress in pharmaceutical research and access planning, patients in Nigeria, Uganda and Kenya continue to face significant barriers to affordable and reliable medicines, particularly for diabetes, cancer and other critical health conditions. In a virtual interview with Access to Medicine Foundation’s Chief Executive Officer, Jayasree K. Iyer and the foundation’s Director of Research, Claudia Martínez, on the 2026 Access to Medicine Index, the foundation examined the gaps in access, the commitments required from pharmaceutical companies and governments, and the role of local manufacturing, partnerships and measurable patient-focused targets in ensuring that medical innovations reach underserved populations. Chiemelie Ezeobi brings excerpts With 95% of projected diabetes growth expected in low- and middle-income countries, what concrete commitments will pharmaceutical companies make to ensure that GLP-1 medicines and insulin become affordable and reliably available to patients in Nigeria, beyond simply registering the drugs? We do not have Nigeria-specific data on the concrete plans pharmaceutical companies have made to ensure newer treatments are available. However, a key finding from the Index highlights that access plans for diabetes treatments in the pipeline tend to focus on more commercially attractive emerging markets, with limited attention to low-income countries such as Nigeria. For GLP-1s that are already on the market, some companies are adopting second brand strategies to launch more affordable versions of their products in certain LMICs, however we did not identify any such strategies for Nigeria. What measurable targets will pharmaceutical companies set to demonstrate that their access-to-medicine commitments are translating into improved patient outcomes in these countries, and how will they be held accountable for meeting those targets? The Index has consistently highlighted the importance of pharmaceutical companies setting clear, measurable and time-bound goals for patient reach, and systematically measuring and reporting progress against these goals. Pharmaceutical companies should establish clear, measurable and time-bound patient reach targets to ensure their access commitments translate into tangible benefits for patients. These targets should be informed by factors such as disease burden, treatment eligibility, and the specific needs of each market. Companies should also systematically measure and report patient reach across their products, countries and target populations. Reporting should be sufficiently disaggregated to show which products, countries and populations are benefiting, providing greater transparency on where progress is being made and where gaps remain. In terms of accountability, several companies have linked executive compensation to patient reach or other access-related metrics, making progress on access part of how leadership performance is assessed. There are also examples of companies, such as Novartis and Sanofi, linking patient reach commitments to sustainability-linked bonds. These arrangements create an additional incentive for companies to deliver on their targets. The 2026 Access to Medicine Index shows that access plans now cover 69 per cent of late-stage pharmaceutical pipeline candidates, more than triple the figure recorded in 2018. However, access to essential medicines remains limited in many low- and middle-income countries. What are the major obstacles preventing pharmaceutical companies from translating these access plans into actual availability and affordability of medicines, particularly in countries like Nigeria? While more companies are planning for access during drug development, having an access plan does not necessarily mean a medicine will become available or affordable. The quality of these plans varies, and some focus primarily on regulatory registration without addressing affordability or sustainable supply. Key barriers include limited healthcare financing, fragmented regulatory and procurement systems, and gaps in health infrastructure. Lower purchasing power and uncertain demand can also make these markets less commercially attractive for pharmaceutical companies. In Nigeria, economic conditions have affected how pharmaceutical companies supply medicines. In 2023, GSK and Sanofi, both assessed in the Index, announced they would end direct commercial operations there and move to third-party distribution. GSK cited foreign exchange shortages and high operating costs as barriers to supplying medicines, while Sanofi also highlighted currency instability and foreign exchange challenges. The report highlights persistent gaps in access to insulin despite growing investments in diabetes research, particularly in newer GLP-1 treatments. What specific measures should pharmaceutical companies and governments take to ensure that essential medicines, especially insulin, remain affordable and accessible to patients in low- and middle-income countries? As newer insulins and GLP-1 therapies emerge, companies and governments must ensure continued access to established essential treatments, particularly human insulin. Key priorities include: Maintaining affordable and reliable insulin supplies: Companies should protect access to human insulin while expanding access to analogue insulins where they offer additional clinical benefits. Setting measurable commitments: Companies should establish transparent targets and indicators for maintaining insulin supply and improving affordability across LMICs. Prioritising underserved populations: Greater attention is needed for LICs, children and young people with type 1 diabetes (T1D), and populations facing unreliable or unaffordable insulin supplies. Strengthening local manufacturing: Companies and governments should leverage manufacturing partnerships to improve regional production, supply security and affordability. Improving monitoring and accountability: Governments should track insulin availability, affordability and access across populations and regions to ensure progress. With cancer products accounting for about half of pharmaceutical clinical candidates and GLP-1 drugs dominating diabetes research, how can pharmaceutical companies ensure that medical innovations reach patients in low- and middle-income countries rather than remaining largely accessible to populations in wealthier markets? Companies should integrate comprehensive access planning during R&D (from phase II onwards), anticipating and proactively addressing the main barriers to access of innovative products in LMICs, including availability, affordability and sustainable supply. While innovation in oncology has delivered significant public health advancements, innovative therapies can present significant access challenges in low-resource settings. For example, their high prices can pose affordability challenges without appropriate equitable pricing considerations that take into account countries’ and patients’ ability to pay. Furthermore, different anticancer targeted therapies require diagnostic testing to identify whether a specific patient population is eligible to benefit from the treatment. Yet, few companies are considering diagnostic access as part of their access planning. Similarly, expanding access to GLP-1 therapies will require companies to develop robust regulatory strategies that include LMICs early in their registration plans, establish appropriate affordability mechanisms, and ensure a reliable and sustainable supply, particularly in the context of high demand in high-income markets. What does the 2026 Index show has improved for Ugandan patients since the previous assessment? The 2026 Access to Medicine Index highlights pharmaceuticals companies’ efforts to address barriers to medicine access across underserved markets, including Uganda. While the Index does not present findings on a country-by-country basis, several examples throughout the report illustrate company initiatives and activities taking place in Uganda. Additional details are also shared with the Index under a non-disclosure agreement. This is why the Index places greater emphasis on transparency, encouraging companies to regularly publish patient reach data and disaggregate these figures to provide a clearer picture of who is benefiting from their programmes. Examples Registration, Uganda has highest number of filings (6) for newer* products among the 26 low-income countries assessed. Uganda also had the highest number of filings for newer* products of all LICs in the 2024 Index, highlighting continued efforts to register products in the country. Whilst registration alone does not guarantee patient access, it is an important first step. *Products that received their first marketing authorisation within the last 5 years. Diabetes: Novo Nordisk’s Changing Diabetes® in Children programme, In Uganda, the programme expanded from reaching around 200 children and young people with type 1 diabetes in 2009 to approximately 4,000 in 2025. However, ensuring continuity of care as young people transition out of these programmes remains an important challenge. Oncology: Bristol Myers Squibb’s collaboration with the Uganda Cancer Institute has supported publicly funded procurement of nivolumab, demonstrating efforts to expand access to innovative cancer treatments. Your report highlights publicly funded access to nivolumab at the Uganda Cancer Institute. How many patients have benefited, who qualifies, and what costs do patients still face? While detailed data on pricing, procurement and number of patients reached, remains under an NDA, the 2026 Index highlights efforts and progress made by Bristol Myers Squibb in expanding access to immuno-oncology treatments, primarily nivolumab (Opdivo) through its Innovative Medicines Access Programme (IMAP), part of its broader ASPIRE strategy. Through IMAP, BMS is working to expand access to nivolumab and other immuno-oncology treatments to more African countries, in both public and private oncology settings. Nivolumab has been supplied to the Uganda Cancer Institute (UCI) through publicly funded procurement mechanism, a change from 2024 when the company was still exploring potential cancer institutes to collaborate with. This is positive progress as immuno-oncology medicines like nivolumab can be expensive and would be financially inaccessible to many patients in Uganda. UCI is the main national cancer referral and treatment center; the agreement therefore opens a channel for patients who previously could not afford it to receive it through the public system. Further details that determine access to the product such as patient’s eligibility criteria, enrollment and funded indications are not publicly available at this stage. The report identifies Roche cancer trials involving Uganda. What commitments ensure that participants can continue receiving treatment after trials end and that successful medicines become affordable to other Ugandan patients? There are several pathways to facilitate access to medicines after clinical trials are conducted, including post-trial access, registration preparation, and affordability considerations. Roche, for example, has a post-trial access policy, and a public commitment to register where clinical trials are conducted. Most of the companies analysed in the Index have similar commitments. The Index assesses whether companies are taking these components into consideration when developing access plans. However, often the number of countries in scope of these access plans are limited: approximately 2% of oncology projects assessed include Uganda, for example. Addressing the referred components in a country-specific manner from the outset will be essential to guarantee access to innovative products. Pathways for facilitating access Post-trial access: companies can commit to providing access to patients benefiting from the trial drug after the trial is concluded, given specific criteria are met. Named patient or compassionate use programmes can also provide additional pathways for patients to access medicines. Registration preparation: companies can start preparing for regulatory registration while these are still ongoing. Although this ensures availability when the product is approved, more measures are required to guarantee access. Affordability: companies can start early to consider countries’ ability to pay and developing equitable pricing plans. Only 19% of the cancer products assessed had access strategies covering low-income countries. What would persuade more companies to make these treatments available and affordable in countries such as Uganda? The opportunity to create sustainable business would persuade more pharmaceutical companies to make treatments available in LICs including Uganda. Three things are particularly important: predictable demand, effective pooled procurement mechanisms and a supportive regulatory environment. Aggregating demand across countries can create economies of scale, reduce transaction costs and give companies greater incentives to offer more affordable prices. Longer-term purchasing commitments and streamlined regulatory processes can further reduce the risks and costs of entering these markets. However, product availability and affordability alone are not enough. Many LICs face wider health system barriers, including gaps in diagnostics, treatment infrastructure and healthcare financing. Addressing these requires collaboration between pharmaceutical companies, governments and local organisations. This year’s Index highlights progress by AstraZeneca, BMS and Roche in expanding access to oncology products in underserved settings, including Uganda. Their approaches demonstrate the importance of addressing barriers across the patient pathway, not just access to medicines, and the value of partnerships in building more sustainable access. The challenge is to create conditions where commercial sustainability and affordable access go hand in hand, ensuring that companies can reach viable markets while more patients benefit from the medicines they need. For a Ugandan family paying for diabetes care out of pocket, what are manufacturers doing to reduce the total cost of insulin, injection supplies and blood-sugar monitoring? There are multiple mechanisms in which the three diabetes-focused companies (Novo Nordisk, Eli Lilly and Sanofi are engaging in initiatives to reduce the price paid by governments and wholesalers in Uganda. Examples of existing initiatives: Novo Nordisk’s Access to Insulin Commitment is an inter-country equitable pricing strategy that targets the public sector in LMICs, under which the ceiling price per human insulin vial is set at 3 USD. Additionally, through its Changing Diabetes® in Children programme, the company provides insulin, syringes and glucometer test strips free of charge to young patients across multiple lower-middle-income countries and LICs. Eli Lilly, utilises technology transfer and supplies its active pharmaceutical ingredient (API) for insulin at a significantly reduced price to EVA Pharma. Lilly has provided a pro-bono technology transfer to enable EVA Pharma to formulate and fill and finish insulin vials and cartridges. This collaboration is part of the Lilly 30×30 initiative. Lilly’s Life for a Child program supports children and youth with diabetes in resource-limited settings by providing insulin, delivery devices, monitoring supplies, medical care, diabetes education, complications screening and management, and advocacy. Sanofi, considers partnerships through its Global Health Unit (GHU). For example, in partnership with mPharma it addresses access pricing and bundled care. Through mPharmas’ Mutti+ platform, diabetes patients obtained medicines at access prices, including selected Sanofi products, alongside free blood glucose testing, consultations and dietary coaching. The program ran from December 2022 to December 2025 that benefitted 387 diabetic patients. At the same time, some companies are slimming down their insulin portfolios and scaling back production of older products and formulations. Examples of implemented approaches include Your report warns that some manufacturers are reducing production of older insulin products. Could this affect supplies to Uganda, and what commitments are companies making to prevent treatment interruptions or forced switches to more expensive products? There is a potential risk to insulin supplies in Uganda. The World Health Organization has warned that manufacturers are phasing out certain older insulin products and formulations, raising concerns about access to affordable treatment in low- and middle-income countries. While Novo Nordisk has committed to maintaining low-cost human insulin supplies, including through a USD 3 per vial ceiling price, this does not cover all discontinued products or guarantee uninterrupted supplies. It is essential that companies work with governments to ensure affordable alternatives are available before products are withdrawn, so patients are not left without treatment. What support is available to Ugandan children with type 1 diabetes, and how can access to insulin be maintained when they become too old for programmes supporting children? In Uganda, children and young people with type 1 diabetes can access support through programmes such as Novo Nordisk’s Changing Diabetes in Children and Life for a Child, supported by Lilly, which provide insulin and essential supplies. Our 2025 report Access to diabetes care for children and young people, highlights how the government provides one free vial of insulin per person per month, but patients needing more must pay for additional supplies. It also finds that these programmes only reach a fraction of those in need, and ensuring continuity of care when young people age out remains a significant challenge. Life for Child (supported by Lily) extended its age limit from 26 to 30, including in Uganda, to help maintain access for longer. However, donations are not a sustainable and long-term solution. As outlined in the 2026 Access to Medicine Index, pharmaceutical companies should identify and prioritise insulin access for underserved populations including children and young people with type 1 diabetes, this includes working with partners such as governments to strengthen national health systems and ensure insulin and essential supplies remain affordable and accessible throughout patients’ lives. What concrete plans do manufacturers have to make newer diabetes medicines, including GLP-1 treatments, affordable in Uganda, beyond simply registering them for sale? We do not have Uganda-specific data on the concrete plans pharmaceutical companies have made to ensure newer treatments are available. However, a key finding from the Index highlights that access plans for diabetes treatments in the pipeline tend to focus on more commercially attractive emerging markets, with limited attention to low-income countries such as Uganda. For GLP-1s that are already on the market, some companies are adopting second brand strategies to launch more affordable versions of their products in certain LMICs, however we did not identify any such strategies for Uganda. Will the insulin manufacturing partnerships in Egypt and South Africa supply Uganda, and is there evidence that patients will benefit from lower prices or more reliable availability? The insulin manufacturing partnership in Egypt does report Uganda as one of the targeted beneficiary countries of the initiative, although clear timelines and supply goals are not reported on a country-level. As for the partnership in South Africa, Uganda is currently not mentioned as a supplied country, although the collaboration is reported to supply additional countries after the initial phase. It is early to say how these two partnerships will directly impact patients. Over time, technology transfers can potentially create conditions for lower insulin prices and improved access. Regional manufacturing can translate into tangible benefits for patients by creating a stronger regional market capable of producing quality medicines competitively, with the potential to improve affordability and availability and ensure supply during global supply chain disruptions. These partnerships have the potential to improve availability and affordability for patients; however, patient-level price and affordability impact data following such initiatives may take time to actualise. Companies should collect and share this data to demonstrate the impact of these partnerships. How do you assess whether these programmes reach low-income patients and people outside Kampala, and what can patients do to find out whether they qualify for support? Local manufacturing initiatives and other partnerships can help support products reach low-income patients by increasing product affordability. Partnerships with local manufacturers have the potential to improve affordability by reducing supply-chain and production costs, strengthening local capacity and supply security, and enabling higher-volume, more predictable production tailored to local and regional demand. Two examples of supply chain capacity building with the aim of improving last-mile delivery and supply to hard-to-reach areas include initiatives from Takeda and Novo Nordisk. Takeda partners with VillageReach in five countries, including Uganda, to strengthen transport systems of products and diagnosis patient samples. Through Changing Diabetes, Novo Nordisk is strengthening cold chain supply mechanisms in Uganda for insulin so that these products can better reach those in hard-to-reach areas. This initiative also involves the distribution of free human insulin for children and youth. Your report highlights promising sickle cell treatments. Is Uganda included in their access plans, and how can companies support affordable access to established treatment while newer medicines are being developed? Yes, in the 2026 Index, Uganda is explicitly included in access plans for two the late-stage sickle cell disease (SCD) candidates assessed. Six companies are currently developing eight projects for SCD. Of these, six are in late-stage development (Phase II onwards), with evidence of access planning for five of the six (83%). These plans typically address multiple access components, including registration plans in low-and middle-income countries, equitable pricing and supply and demand planning. It is important that innovation includes children, especially as new gene therapies remain prohibitively expensive in low-resource settings. Yet only half of candidate drugs for sickle cell disease in the 2026 Index are being tested in children under 12 years of age. Ensuring continued and equitable access to established treatments remains essential. For example, Novartis’s sub-Saharan Africa business unit continues with its sickle cell disease (SCD) programme in Uganda in collaboration with the Ministry of Health and other key stakeholders. Mental health has some of the weakest access planning in the Index. What would it take to ensure that Ugandans with conditions such as depression, bipolar disorder and schizophrenia can obtain affordable treatment consistently? Recognising that access to mental healthcare requires a holistic approach considering many components including disease awareness, workforce capacity, timely diagnosis and ultimately the availability and affordability of pharmacological treatment, the Index highlights significant gaps in mental health innovation pipelines and access planning. Access planning for projects in the pipeline covers only 5/13 (38%) of late-stage projects, focusing mainly on registration and including on average one country in scope. None of the access plans includes Uganda. Future access plans will need to be implemented early and move beyond registration to address affordability for lower-income groups and consider partnerships that can support appropriate uptake and use. Which emerging malaria treatments and HIV-prevention options highlighted in the report could be most relevant to Uganda, and what needs to happen before patients can realistically access them? The 2026 Key Finding for access planning identifies two emerging treatments for HIV prevention and malaria that are relevant to Uganda. Ganaplacide/lumefantrine (Novartis/Medicines for Malaria Venture (MMV)), is an antimalarial in Phase III trials that could offer an important alternative to existing treatments as resistance to current antimalarial medicines becomes an increasing concern. For HIV prevention, MSD’s alimatravir could offer a promising option as a potential first long-acting oral PrEP option, which could simplify administration (compared with injectable options that are currently available), while supporting adherence. As highlighted in the Index, both developments are comprehensively targeting access barriers, the former through a partnership with MMV and the latter through a non-exclusive voluntary licensing agreement (NEVL) with generic manufacturers, one of which is based in Uganda (Qcil). However, the NEVL is only the first step, and access ultimately depends on successful approval registration and affordable supply in Uganda. Pharmaceutical companies have a responsibility to ensure their products are registered, affordable, and reliably supplied. However, more broadly speaking, effective distribution networks, access to diagnostics and a well-functioning health system are also needed to overcome barriers on the ground. Therefore, working with partners including governments is crucial to reach patients, particularly those in underserved communities. What specific commitments on prices, supply, patient access and measurable improvements should we expect companies to demonstrate within a year? While progress within a year may be difficult to assess, the Index looks for the evidence of measurable impact on people living in LMICS. Companies should go beyond reporting on commitments and initiatives to provide evidence of their impact, including patient reach, improved affordability and availability, and sustained access over time. Build on existing progress in tracking the outcomes by reporting how many patients are being reached, with which products and in which countries, enables a more transparent assessment of whether companies are reaching their intended access goals and targets. Additionally, the Foundation looks for evidence of expanding access in low-income countries (LICs): At current, only 36% of assessed products have a country-specific access strategy in LICs, compared with 80% in lower-middle-income countries (LMICs) and 85% in upper-middle-income countries (UMICs). Based on our analysis, the Index identifies tailored opportunities for each company that set guidance and expectations for increased access over the coming 2 years. They highlight current gaps and build on existing work and initiatives undertaken by the companies and/or their commercial presence. 9 out of the 20 companies (in the 2026 Index) have opportunities that focus on Africa/SSA, indicating that Africa, and especially Sub-Saharan Africa (SSA), continue to have long standing gaps. The potential to close the gaps lies in these opportunities, from broader registration to local manufacturing. Novartis has maintained its top position in the 2026 Index, with GSK ranking second. Beyond these rankings, how can we measure whether pharmaceutical companies are genuinely improving access to medicines for patients in African countries such as Kenya? The ranking and company report cards provide a comprehensive overview of progress in improving access to medicine, assessing company (and industry) efforts across the spectrum, from governance and research and development (R&D) to product delivery. To gain a deeper understanding of how companies are translating these efforts into improved access at the country level, the Index collects and evaluates company-reported data against a range of indicators. In R&D, Kenya, alongside South Africa, stands out for its inclusion in clinical trials, helping to promote more equitable access to innovative medicines and support the development of locally informed clinical guidelines. This is particularly evident in Roche’s work, recognised as a Best Practice for expanding the geographic reach of its oncology clinical trials. In addition, 5 companies provide Kenyans access to products through inclusive business models, designed to support the sustainable availability of selected company products for populations in low- and middle-income countries (LMICs) who are unserved by existing business models. These approaches aim to address access barriers through partnerships, often combining affordability strategies, local manufacturing and tailored procurement pathways. For example, In June 2025, the Kenyan Ministry of Health and Pfizer launched the Accord in Kenya, enabling the Kenya Medical Supplies Agency (KEMSA), the medical logistics provider for the ministry’s public health facilities and programmes, to procure Pfizer’s full portfolio of medicines and vaccines on a not-for-profit basis. The Index shows that pharmaceutical companies are making progress in developing cancer medicines, but access remains uneven, particularly in lower-income countries. What practical measures can be taken to ensure that cancer patients in Kenya benefit from these innovations, especially given the high costs of diagnosis and treatment? Firstly, companies can embed high burden countries early in oncology R&D by co-designing access plans with LMIC research partners and clinical trial centres. Secondly, expand the depth and geographic scope of access planning and strategies. Plans should look beyond registration and post-trial access to address barriers across the product pathway – including inclusive clinical trials, diagnostics and biomarker testing, affordability, reimbursement and reliable supply. Companies should also make greater use of mechanisms that can enable affordable access at scale, including voluntary licensing, which remains underused for relevant products. Finally, build towards sustainable and equitable delivery at scale. This can be done by forming partnerships with national and local stakeholders to address needs across cancer care, including screening and diagnosis, affordability and treatment. Start by identifying existing cancer programmes and treatment centres in LMICs, and partner with them to strengthen and build on these initiatives, for example, through affordability measures targeted at underserved patients, and training of healthcare workers. Successful approaches can then be scaled more broadly. The report highlights growing investment in GLP-1 medicines for diabetes, yet access to affordable treatment remains a challenge. At the same time, GLP-1 drugs such as Ozempic and Mounjaro are becoming increasingly popular for weight loss, including here in Kenya. What are pharmaceutical companies doing to address this growing demand while ensuring that patients who need these medicines for diabetes treatment can still access them affordably and consistently? While pharmaceutical companies cannot directly control which patients are prescribed GLP-1 medicines, they do have a responsibility to ensure that growing demand does not come at the expense of equitable access. Our 2026 Index shows that companies are investing heavily in GLP-1 medicines, but more needs to be done to ensure they are affordable and accessible. Only two of the 10 access plans assessed for late-stage diabetes treatments included equitable pricing measures, and none covered low-income countries. While some companies are adopting strategies to improve affordability, such as introducing lower-priced second brands, access to these medicines remains limited in many low- and middle-income countries. As demand grows for both diabetes and obesity treatment, companies need to expand sustainable supply and introduce affordable pricing strategies to ensure these medicines reach patients who need them, particularly in low- and middle-income countries. The report highlights the potential of local pharmaceutical manufacturing and partnerships to improve access to essential medicines, particularly insulin. What opportunities exist for Kenya and the wider East African region to strengthen local pharmaceutical manufacturing? What role should global pharmaceutical companies play, and what concrete steps should the Kenyan government, particularly the Ministry of Health, take to support local production and improve the affordability and availability of essential medicines? Kenya has an ongoing pharmaceutical manufacturing partnership between Universal Corporate Limited and Merck KGaA for the manufacture of pediatric praziquantel for schistosomiasis. This is a unique partnership between one of the large pharmaceutical companies and East Africa, especially for the manufacture of insulin. To meaningfully build lasting capacity, global pharmaceutical companies can build partnerships with local manufacturers with the aim of manufacturing priority products and with the goal of sustained independence for the local partner. The Kenyan government plays a key role in identifying products that are viable for local production, and in creating an enabling environment for it. The Kenya Health Products and Technologies Local Manufacturing Strategy 2026-2030 shows strong commitment to support local manufacturing over the next years. The Ministry should ensure that this strategy translates into implementation through commitment and policies that support procurement from local manufacturers and continue to support the country in reaching WHO Maturity Level 3 status. Government investments and policies should also help establish the necessary workforce and infrastructure needed to take up and sustain local production. Pharmaceutical companies can also weigh in here, for example by supporting Universities in providing courses in pharma manufacturing.

Original Source

Read the full article at Thisdaylive →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.